Advent International, a United States-based global private equity company, has entered into discussions to acquire Zentiva, Sanofi's European generics business, it is reported today.
The deal is valued at EUR1.9bn and it is likely to be completed by the end of 2018, subject to execution of definitive agreements, followed by approvals from relevant regulatory authorities among other conditions.
Sanofi is looking to sell Zentiva after considering the European generics business to be non-core. The deal is also part of the French drugmaker's strategy to simplify and reshape its overall business. Czech Republic-based Zentiva has a generics portfolio that includes several therapeutic areas like cardiovascular, central nervous system, anti-infectives, anti-inflammatory and pain, and respiratory.
Tempus selected by ARPA-H to provide CRO and testing services for ADAPT cancer programme
Polarean expands Ascend Imaging partnership to boost US market reach
Merck's WINREVAIR reduces clinical worsening by 76% in early PAH patients
Polarean Imaging signs new supply agreementwith UVA Health for clinical Xenon MRI
PureTech reports positive extension data for Deupirfenidone in IPF
Redx reports positive Phase 2a data for zelasudil in idiopathic pulmonary fibrosis
Generate:Biomedicines reports results from Phase 1 study of GB-0895
Sichuan Kelun-Biotech Biopharmaceutical NDA for A400 accepted for review in China
Akeso showcasing late-breaking abstract from ivonescimab study at ESMO
TransMedics and Mercedes-Benz to launch dedicated organ transport network in Italy
N4 Pharma advances RNA delivery breakthrough with SRI collaboration
CorestemChemon presents Neuronata-R Phase 3 results at PACTALS 2025
AstraZeneca's Fasenra misses primary endpoint in Phase III COPD trial